EP Patent

EP3143005B1 — Chemokine cxcr4 and ccr5 receptor modulators and used related thereto

Assigned to Emory University · Expires 2021-07-07 · 5y expired

What this patent protects

Patent listed against Xolremdi.

Drugs covered by this patent

Patent Metadata

Patent number
EP3143005B1
Jurisdiction
EP
Classification
—
Expires
2021-07-07
Drug substance claim
No
Drug product claim
No
Assignee
Emory University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.